Quick Summary
- Clover Health (CLOV) shares jumped nearly 14% to $4.89 following CMS’s decision to raise its Medicare star rating from 3.5 to 4.5 stars.
- The rating adjustment came after a U.S. District Court mandated CMS to recalculate ratings for Clover’s H5141 PPO Medicare Advantage contract.
- This improved rating will impact 2027 reimbursement rates and qualifies Clover for quality bonus payments from federal programs.
- Shares touched an intraday 52-week peak of $5.14, marking the third consecutive session of gains.
- CLOV’s rally occurred against a backdrop of market-wide declines, with major indices closing in the red.
Shares of Clover Health (CLOV) climbed 13.99% on Wednesday, finishing at $4.89 after reaching an intraday peak of $5.14, driven by news that the Centers for Medicare & Medicaid Services had significantly upgraded the company’s Medicare star rating.
Clover Health Investments, Corp., CLOV
The healthcare technology company extended its winning streak to three sessions while notching a fresh 52-week high.
The driving force: CMS revised CLOV’s 2026 Medicare star rating upward to 4.5 stars from 3.5 stars after a court decision mandated the recalculation.
This revised rating pertains to Contract H5141, the company’s PPO Medicare Advantage offering, which serves over 97% of Clover’s membership base.
The enhanced rating carries direct financial implications, affecting 2027 government payment rates and opening the door to CMS quality bonus payments — tangible revenue gains beyond just improved perception.
Court Battle Delivers Rating Victory
The rating revision emerged from legal proceedings rather than a routine administrative update. Clover initiated litigation against CMS and the Department of Health and Human Services, challenging the agency’s use of what it deemed “improper” measurement criteria and calculation methods in determining the initial 3.5-star rating.
Clover contended that a 4.0-star rating was warranted, and that the lower designation would inflict substantial financial damage through lost quality bonuses and reduced government payments, while hampering competitive positioning and constraining expansion prospects.
On May 29, 2026, the U.S. District Court for the Southern District of Georgia ruled in Clover’s favor, invalidating the original rating and directing CMS to perform a fresh calculation.
CMS communicated the revised 4.5-star rating to Clover on June 9 — exceeding the company’s own initial projection of 4.0 stars.
Strong Earnings Provide Additional Momentum
The star rating announcement built upon an already strengthening operational foundation.
Clover delivered its inaugural positive GAAP net income during Q1 2026, accompanied by robust year-over-year revenue expansion.
Canaccord analyst Richard Close recently lifted his price target on CLOV shares while maintaining his Buy recommendation. Close pointed to favorable industry trends in managed care benefiting digital healthcare platforms.
This positive fundamental context encouraged investors to act decisively on Wednesday’s regulatory development.
The stock’s performance was particularly remarkable considering broader market conditions that day.
The May 2026 Consumer Price Index data, published Wednesday morning, revealed headline inflation accelerating to 4.2% annually — the highest reading since 2023 — fueled by surging energy prices linked to international tensions.
The S&P 500, Dow Jones Industrial Average, and Nasdaq all posted losses during the trading session as investors digested the inflation data.
CLOV defied the negative market sentiment entirely, propelled by a company-specific legal victory with measurable financial benefits.
CMS officially communicated the upgraded 4.5-star rating to Clover Health on June 9, 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
